X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (10) 10
adult (9) 9
human immunodeficiency virus--hiv (9) 9
humans (9) 9
female (8) 8
hiv infections - drug therapy (8) 8
male (8) 8
drug therapy (7) 7
middle aged (7) 7
abridged index medicus (6) 6
antiretroviral drugs (6) 6
treatment outcome (6) 6
anti-hiv agents - therapeutic use (5) 5
clinical trials (5) 5
double-blind method (5) 5
drug administration schedule (5) 5
emtricitabine (5) 5
hiv (5) 5
infectious diseases (5) 5
internal medicine (5) 5
medicine, general & internal (5) 5
tenofovir (5) 5
viral load (5) 5
anti-hiv agents - adverse effects (4) 4
antiretroviral therapy (4) 4
cd4 antigen (4) 4
hiv infection (4) 4
hiv infections - virology (4) 4
hiv-1 (4) 4
infections (4) 4
safety (4) 4
adenine - analogs & derivatives (3) 3
adults (3) 3
analysis (3) 3
cd4 lymphocyte count (3) 3
combination therapy (3) 3
drug therapy, combination (3) 3
drugs (3) 3
hiv-1 - drug effects (3) 3
infection (3) 3
infectious disease (3) 3
raltegravir potassium (3) 3
research (3) 3
rna, viral - blood (3) 3
rna-directed dna polymerase (3) 3
tablets (3) 3
viral load - drug effects (3) 3
abacavir (2) 2
abacavir-lamivudine (2) 2
acquired immune deficiency syndrome--aids (2) 2
adenine - administration & dosage (2) 2
adenine - therapeutic use (2) 2
aged (2) 2
antiretroviral agents (2) 2
antiviral agents (2) 2
bone-mineral density (2) 2
cholesterol (2) 2
clinical medicine (2) 2
cobicistat (2) 2
cross infection (2) 2
daily lopinavir/ritonavir (2) 2
deoxycytidine - analogs & derivatives (2) 2
diarrhea (2) 2
dosage and administration (2) 2
double-blind (2) 2
drug combinations (2) 2
drug dosages (2) 2
efavirenz (2) 2
exposure (2) 2
heterocyclic compounds, 3-ring - adverse effects (2) 2
hiv integrase inhibitors - administration & dosage (2) 2
hiv protease inhibitors - administration & dosage (2) 2
hiv protease inhibitors - adverse effects (2) 2
hiv-1 - genetics (2) 2
hiv-1 - isolation & purification (2) 2
immunology (2) 2
inhibitors (2) 2
initial treatment (2) 2
integrase inhibitor raltegravir (2) 2
lamivudine (2) 2
lipids (2) 2
lopinavir (2) 2
mortality (2) 2
motivation (2) 2
mutation (2) 2
nosocomial infections (2) 2
nucleosides (2) 2
nucleotides (2) 2
patients (2) 2
pharmacokinetics (2) 2
pyrimidinones - adverse effects (2) 2
pyrimidinones - therapeutic use (2) 2
pyrrolidinones - administration & dosage (2) 2
pyrrolidinones - adverse effects (2) 2
pyrrolidinones - therapeutic use (2) 2
randomization (2) 2
ribonucleic acid--rna (2) 2
ritonavir (2) 2
ritonavir - adverse effects (2) 2
ritonavir - therapeutic use (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9787, pp. 229 - 237
Summary Background The non-nucleoside reverse transcriptase inhibitor (NNRTI), rilpivirine (TMC278; Tibotec Pharmaceuticals, County Cork, Ireland), had... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | ZIDOVUDINE | COMBINATION THERAPY | ACTIVE ANTIRETROVIRAL THERAPY | EMTRICITABINE | PROTEASE-INHIBITOR | CYSTATIN-C | CREATININE | DAILY LAMIVUDINE | NEVIRAPINE | TENOFOVIR | Rilpivirine | HIV Reverse Transcriptase - antagonists & inhibitors | Humans | Middle Aged | Male | Anti-HIV Agents - administration & dosage | Nitriles - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Nucleotides - therapeutic use | Adenine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Reverse Transcriptase Inhibitors - therapeutic use | Acquired Immunodeficiency Syndrome - virology | Acquired Immunodeficiency Syndrome - ethnology | Emtricitabine | Nucleosides - therapeutic use | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Organophosphonates - therapeutic use | HIV-1 - drug effects | Pyrimidines - administration & dosage | Anti-HIV Agents - adverse effects | Benzoxazines - adverse effects | Treatment Outcome | HIV-1 - genetics | Acquired Immunodeficiency Syndrome - drug therapy | Benzoxazines - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Mutation | Nitriles - adverse effects | Viral Load - drug effects | Deoxycytidine - analogs & derivatives | Nitriles - therapeutic use | Evaluation | Patient outcomes | Clinical trials | Dosage and administration | Drug therapy | HIV infection | Design | Antiretroviral drugs | Corporate sponsorship | Human immunodeficiency virus--HIV | Technological change | Research | Clinical medicine | Drugs | RNA-directed DNA polymerase | Exanthema | antiretroviral therapy | Lamivudine | Lipids | Nucleotides | Regression analysis | Efavirenz | CD4 antigen | nucleosides | Algorithms | Hospitals | non-nucleoside reverse transcriptase inhibitors | Abacavir | Zidovudine | Pharmaceuticals
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2016, Volume 16, Issue 1, pp. 43 - 52
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9987, pp. 2606 - 2615
Summary Background Tenofovir disoproxil fumarate can cause renal and bone toxic effects related to high plasma tenofovir concentrations. Tenofovir alafenamide... 
Internal Medicine | KIDNEY-DISEASE | RATES | MEDICINE, GENERAL & INTERNAL | ABACAVIR-LAMIVUDINE | BONE-MINERAL DENSITY | SAFETY | ADULTS | ANTIRETROVIRAL THERAPY | LOPINAVIR/RITONAVIR | COUNT | EXPOSURE | Humans | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Arthralgia - chemically induced | Thiazoles - adverse effects | Sleep Initiation and Maintenance Disorders - chemically induced | Tenofovir | Adenine - adverse effects | Quinolones - adverse effects | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Headache - chemically induced | Emtricitabine | Adenine - analogs & derivatives | Kidney - drug effects | Respiration Disorders - chemically induced | Double-Blind Method | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | HIV Infections - virology | Organophosphonates - adverse effects | Treatment Outcome | CD4 Lymphocyte Count | Nausea | Adenine - administration & dosage | Organophosphonates - administration & dosage | Bone Density - drug effects | Quinolones - administration & dosage | Carbamates - adverse effects | HIV Infections - drug therapy | Viral Load - drug effects | Cobicistat | Deoxycytidine - analogs & derivatives | Drug Combinations | Medical colleges | Clinical trials | Cross infection | Nosocomial infections | HIV (Viruses) | Drug therapy | Health aspects | HIV infection | Analysis | Antiretroviral drugs | Infections | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV
Journal Article
Lancet, The, ISSN 0140-6736, 2010, Volume 375, Issue 9712, pp. 396 - 407
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2011, Volume 11, Issue 12, pp. 907 - 915
Journal Article
Lancet, The, ISSN 0140-6736, 2008, Volume 372, Issue 9639, pp. 646 - 655
Journal Article
Lancet, The, ISSN 0140-6736, 2013, Volume 382, Issue 9893, pp. 700 - 708
Journal Article